新型冠狀病毒肺炎（COVID-19）仍在全球范圍內(nèi)傳播，尚無特效藥應(yīng)用于臨床。烏司他?。╱linastatin）在抗炎方面發(fā)揮重要作用，臨床上主要應(yīng)用于急性胰腺炎、休克和彌散性血管內(nèi)凝血等，其還具有抗氧化應(yīng)激、抗凝、免疫調(diào)節(jié)作用，可能對(duì)于降低COVID-19的嚴(yán)重程度和死亡率有重要意義。主要結(jié)合烏司他丁的藥理作用及其在治療急性呼吸窘迫綜合征、膿毒癥肺損傷等COVID-19并發(fā)癥中的臨床應(yīng)用，論述其應(yīng)用于COVID-19的可行性，以期為該病的臨床治療及新藥研發(fā)提供幫助。

Coronavirus disease 2019 (COVID-19) is still spreading worldwide. At present, no specific drug has been developed for the virus. Ulinastatin plays an important role in anti-inflammatory. Clinically, it is mainly used in acute pancreatitis, shock and disseminated intravascular coagulation. It also has the effects of antioxidant stress, anticoagulation and immune regulation, which may be of great significance to reduce the severity and mortality of COVID-19. Combined with the pharmacological effect of ulinastatin and its clinical application in the treatment of COVID-19 complications such as acute respiratory distress syndrome and sepsis lung injury, this paper discusses the feasibility of its application in COVID-19, so as to provide help for the clinical treatment and new drug research and development of this disease.

R978.7;R974

山東省醫(yī)藥衛(wèi)生科技發(fā)展計(jì)劃項(xiàng)目（2019WS605，202104110334，202104110339，202104010549）；濰坊市科技發(fā)展計(jì)劃項(xiàng)目（2021YX028）；濰坊醫(yī)學(xué)院大學(xué)生創(chuàng)新創(chuàng)業(yè)培訓(xùn)項(xiàng)目（X2021523，X2021516）#共同